MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
11.46
-0.23 (-1.97%)
At close: Jul 1, 2026, 4:00 PM EDT
11.48
+0.02 (0.17%)
After-hours: Jul 1, 2026, 7:53 PM EDT
MiNK Therapeutics Employees
MiNK Therapeutics had 15 employees as of December 31, 2025. The number of employees decreased by 8 or -34.78% compared to the previous year.
Employees
15
Change (1Y)
-8
Growth (1Y)
-34.78%
Revenue / Employee
n/a
Profits / Employee
-$831,329
Market Cap
57.09M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | -8 | -34.78% |
| Dec 31, 2024 | 23 | -8 | -25.81% |
| Dec 31, 2023 | 31 | -6 | -16.22% |
| Dec 31, 2022 | 37 | 4 | 12.12% |
| Dec 31, 2021 | 33 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 139 |
| Xilio Therapeutics | 76 |
| aTyr Pharma | 60 |
| PMV Pharmaceuticals | 54 |
| Boundless Bio | 28 |
| Filana Therapeutics | 20 |
| Context Therapeutics | 15 |
| Dogwood Therapeutics | 8 |
INKT News
- 14 days ago - MiNK Therapeutics Transcript: AGM 2026 - Transcripts
- 4 weeks ago - MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting - GlobeNewsWire
- 4 weeks ago - MiNK Therapeutics doses first patient in agenT-797 trial - TheFly
- 4 weeks ago - MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness - GlobeNewsWire
- 6 weeks ago - MiNK Therapeutics reports new data on agenT-797 at ATS 2026 - TheFly
- 6 weeks ago - MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications - GlobeNewsWire
- 6 weeks ago - MiNK Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 6 weeks ago - MiNK Therapeutics Earnings release: Q1 2026 - Filings